Grifols SA
GRFS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001438569
No open-market purchases or sales by Grifols SA insiders were filed in the last 90 days; 166 institutions reported holding it in 13F filings for Q2 2026, worth $1.01B in total; no superinvestor holds it.
- Currency
- EUR
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 14, 2026, 1:13 AM ET
Amounts are in EUR, the currency Grifols SA reports in. Lines marked ≈ US$ convert key figures to US dollars.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F |
| Reported | – | – | – | – | – |
| Revenue | EUR 7.21B≈ US$7.80B | EUR 6.59B≈ US$7.13B | EUR 6.06B≈ US$6.39B | EUR 4.93B≈ US$5.84B | EUR 5.34B≈ US$6.09B |
| Cost of revenue | EUR 4.42B | EUR 4.10B | EUR 3.83B | EUR 2.97B | EUR 3.08B |
| Gross profit | EUR 2.79B | EUR 2.49B | EUR 2.23B | EUR 1.96B | EUR 2.26B |
| Operating expenses | EUR 1.64B | EUR 1.76B | EUR 1.55B | EUR 1.42B | EUR 1.28B |
| Research and development | EUR 384.0M | EUR 395.3M | EUR 361.1M | EUR 354.9M | EUR 294.2M |
| Selling, general and administrative | EUR 1.26B | EUR 1.37B | EUR 1.19B | EUR 1.06B | EUR 985.6M |
| Operating income | EUR 1.19B | EUR 799.4M | EUR 805.7M | EUR 595.1M | EUR 996.1M |
| Interest expense | EUR 714.8M | EUR 596.9M | EUR 496.5M | EUR 278.0M | EUR 249.6M |
| Income tax | EUR 231.2M | EUR 43.3M | EUR 90.1M | EUR 85.1M | EUR 169.6M |
| Net income | EUR 212.8M≈ US$230.3M | EUR 180.7M≈ US$195.4M | EUR 271.1M≈ US$285.6M | EUR 265.3M≈ US$313.9M | EUR 709.0M≈ US$809.0M |
| EPS, basic | EUR 0.23 | EUR 0.09 | EUR 0.31 | EUR 0.28 | EUR 0.90 |
| EPS, diluted | EUR 0.23 | EUR 0.09 | EUR 0.31 | EUR 0.28 | EUR 0.90 |
| Weighted shares, basic | 679.7M | 679.8M | 679.8M | 681.6M | 685.5M |
| Weighted shares, diluted | 679.9M | 677.1M | 679.3M | 681.4M | 685.1M |
| Margins and growth | |||||
| Gross margin | 38.7% | 37.8% | 36.8% | 39.8% | 42.2% |
| Operating margin | 16.5% | 12.1% | 13.3% | 12.1% | 18.7% |
| Net margin | 3.0% | 2.7% | 4.5% | 5.4% | 13.3% |
| Revenue growth, year over year | +9.4% | +8.7% | +22.9% | −7.6% | +4.7% |
| Net income growth, year over year | +17.8% | −33.4% | +2.2% | −62.6% | +9.3% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F |
| Reported | – | – | – | – | – |
| Cash and equivalents | EUR 979.8M | EUR 529.6M | EUR 548.0M | EUR 655.5M | EUR 579.6M |
| Short-term investments | EUR 237.5M | EUR 116.6M | EUR 31.0M | EUR 2.03B | EUR 11.1M |
| Accounts receivable | EUR 705.5M | EUR 645.1M | EUR 608.7M | EUR 432.2M | EUR 383.2M |
| Inventory | EUR 3.56B | EUR 3.46B | EUR 3.20B | EUR 2.26B | EUR 2.00B |
| Total current assets | EUR 5.73B | EUR 6.45B | EUR 4.65B | EUR 5.51B | EUR 3.16B |
| Property, plant and equipment | EUR 3.34B | EUR 3.25B | EUR 3.27B | EUR 2.55B | EUR 2.32B |
| Goodwill | EUR 7.40B | EUR 6.80B | EUR 7.01B | EUR 6.23B | EUR 5.33B |
| Intangible assets | EUR 2.93B | EUR 2.83B | EUR 2.95B | EUR 1.64B | EUR 1.56B |
| Total assets | EUR 21.4B≈ US$22.2B | EUR 21.4B≈ US$23.7B | EUR 21.5B≈ US$23.0B | EUR 19.2B≈ US$21.8B | EUR 15.3B≈ US$18.7B |
| Accounts payable | EUR 1.12B | EUR 960.8M | EUR 862.3M | EUR 785.3M | EUR 746.2M |
| Total current liabilities | EUR 2.16B | EUR 2.32B | EUR 1.96B | EUR 3.47B | EUR 1.34B |
| Long-term debt | EUR 2.34B | EUR 3.65B | EUR 3.59B | EUR 3.58B | EUR 3.30B |
| Total liabilities | EUR 12.8B | EUR 13.5B | EUR 13.1B | EUR 11.9B | EUR 8.55B |
| Shareholders' equity | EUR 8.61B | EUR 7.97B | EUR 8.46B | EUR 7.32B | EUR 6.72B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
| Filing | 20-F | 20-F | 20-F | 20-F | 20-F |
| Reported | – | – | – | – | – |
| Operating cash flow | EUR 902.2M≈ US$976.1M | EUR 208.3M≈ US$225.3M | EUR -10.9M≈ US-$11.4M | EUR 597.0M≈ US$706.2M | EUR 1.11B≈ US$1.27B |
| Capital expenditures | EUR 232.5M | EUR 209.5M | EUR 266.5M | EUR 247.4M | EUR 280.2M |
| Free cash flow | EUR 669.6M≈ US$724.5M | EUR -1.25M≈ US-$1.36M | EUR -277.4M≈ US-$292.2M | EUR 349.6M≈ US$413.6M | EUR 830.2M≈ US$947.3M |
| Depreciation and amortization | EUR 437.9M | EUR 441.9M | EUR 407.9M | EUR 359.8M | EUR 321.5M |
| Dividends paid | EUR 962.0K | EUR 0 | EUR 592.0K | EUR 258.9M | – |
| Share buybacks | – | EUR 0 | EUR 3.46M | EUR 125.7M | – |
| Investing cash flow | EUR 886.7M | EUR -397.6M | EUR -1.98B | EUR -854.1M | EUR -858.1M |
| Financing cash flow | EUR -1.36B | EUR 186.0M | EUR -173.5M | EUR 2.30B | EUR -354.4M |
| Net change in cash | EUR 450.2M | EUR -18.4M | EUR -2.13B | EUR 2.10B | EUR -162.3M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Grifols SA reports no single share count on its 10-K and 10-Q covers. Companies with several share classes report one count per class, which this data doesn't include.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- ≈ US$ figures convert EUR at FRED H.10 exchange rates (Federal Reserve): the average rate over the period for income and cash flow, and the rate on the period-end date, or the last business day before it, for the balance sheet.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.